The metabolic syndrome: Time for a critical appraisal - Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

被引:1561
作者
Kahn, R
Buse, J
Ferrannini, E
Stern, M
机构
[1] Amer Diabet Assoc, Alexandria, VA 22311 USA
[2] Univ N Carolina, Sch Med, Div Endocrinol & Gen Med & Clin Epidemiol, Chapel Hill, NC USA
[3] Univ Pisa, Sch Med, Dept Internal Med, I-56100 Pisa, Italy
[4] Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, San Antonio, TX 78284 USA
关键词
D O I
10.2337/diacare.28.9.2289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The term "metabolic syndrome" refers to a clustering of specific cardiovascular disease (CVD) risk factors whose underlying pathophysiology is thought to be related to insulin resistance. Since the term is widely used in research and clinical practice, we undertook an extensive review of the literature in relation to the syndrome's definition, underlying pathogenesis, and association with CVD and to the goals and impact of treatment. While there is no question that certain CVD risk factors are prone to cluster, we found that the metabolic syndrome has been imprecisely defined, there is a lack of certainty regarding its pathogenesis, and there is considerable doubt regarding its value as a CVD risk marker. Our analysis indicates that too much critically important information is missing to warrant its designation as a "syndrome." Until much needed research is completed, clinicians should evaluate and treat all CVD risk factors without regard to whether a patient meets the criteria for diagnosis of the "metabolic syndrome."
引用
收藏
页码:2289 / 2304
页数:16
相关论文
共 170 条
[1]   CAROTID-ARTERY WALL INTIMA-MEDIA THICKNESS IS ASSOCIATED WITH INSULIN-MEDIATED GLUCOSE DISPOSAL IN MEN AT HIGH AND LOW CORONARY RISK [J].
AGEWALL, S ;
FAGERBERG, B ;
ATTVALL, S ;
WENDELHAG, I ;
URBANAVICIUS, V ;
WIKSTRAND, J .
STROKE, 1995, 26 (06) :956-960
[2]   NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older [J].
Alexander, CM ;
Landsman, PB ;
Teutsch, SM ;
Haffner, SM .
DIABETES, 2003, 52 (05) :1210-1214
[3]  
[Anonymous], 2005, DIABETES CARE, V28, pS4
[4]  
[Anonymous], 2005, The IDF consensus worldwide definition of the metabolic syndrome
[5]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[6]  
Avogaro P, 1967, ACTA DIABETOLLAT, V4, P36
[7]  
Balkau B, 2002, DIABETES METAB, V28, P364
[8]  
BALTIMORE MD, 2000, STEDMANS MED DICT, P1746
[9]   Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 3 diabetes [J].
Bruno, G ;
Merletti, F ;
Biggeri, A ;
Bargero, G ;
Ferrero, S ;
Runzo, C ;
Cerai, SP ;
Pagano, G ;
Cavallo-Perin, P .
DIABETES CARE, 2004, 27 (11) :2689-2694
[10]   Intra-abdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome [J].
Carr, DB ;
Utzschneider, KM ;
Hull, RL ;
Kodama, K ;
Retzlaff, BM ;
Brunzell, JD ;
Shofer, JB ;
Fish, BE ;
Knopp, RH ;
Kahn, SE .
DIABETES, 2004, 53 (08) :2087-2094